Wall Street analysts expect Jaguar Health Inc (NASDAQ:JAGX) to announce ($5.61) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Jaguar Health’s earnings. The lowest EPS estimate is ($5.92) and the highest is ($5.29). Jaguar Health reported earnings of ($53.15) per share in the same quarter last year, which indicates a positive year over year growth rate of 89.4%. The firm is scheduled to report its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that Jaguar Health will report full-year earnings of ($6.07) per share for the current year, with EPS estimates ranging from ($6.23) to ($5.90). For the next fiscal year, analysts forecast that the business will post earnings of $0.03 per share, with EPS estimates ranging from $0.00 to $0.05. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Jaguar Health.
Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($13.29) by $0.70. Jaguar Health had a negative net margin of 667.59% and a negative return on equity of 372.84%. The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $2.20 million.
Shares of Jaguar Health stock traded down $0.63 during trading on Monday, hitting $1.96. The company’s stock had a trading volume of 1,819,274 shares, compared to its average volume of 442,654. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.30 and a quick ratio of 0.18. The business’s fifty day moving average price is $4.21. Jaguar Health has a 52 week low of $1.85 and a 52 week high of $175.00.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.